HypertensionNCT07879755
An Extension Trial of GW 906 in Participants With Essential Hypertension
A study testing GW906 in people with Hypertension, run by Shenzhen Salubris Pharmaceuticals Co., Ltd. at 1 site in China.
Trial summary
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906 Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- GW906
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,500 participants
- Where
- 1 siteChina
- Study dates
- 12 Jun 2026to 30 Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Completed study treatment and the study in accordance with the protocol for GW906 injection.
- Willing to participate in the study and provide written informed consent.
Who cannot join
- Secondary hypertension.
- Orthostatic hypotension accompanied by hypotension-related symptoms was observed in a prior study of GW906 injection.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; International normalized ratio (INR) > 2.0; Serum potassium > 5.0 mmol/L or < 3.5 mmol/L; eGFR≤30 mL/min/1.73m^2.
- History of any cardiovascular event within 6 months.
- Patients with active malignancy or a history of malignancy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Shanghai Jiao Tong University School of Medicine, Ruijin Hospital
Shanghai, Shanghai Municipality, 200025
Jiguang Wang, Professor, +86-13764189476, jiguangwang@rjh.com.cn
About this study
Official title: An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of GW906 (SAL0132) Injection in Patients With Essential Hypertension
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906
Read the detailed description
This is an open-label, multicenter, non-randomized, long term extension study. Total study duration is expected to be up to 2 years, with a maximum of 3 years. Participants who have completed the previous GW906 Injection study will be assessed for eligibility at the screening visit of this study. Those who meet the eligibility criteria will receive the first dose of the extension treatment. Participants enrolled in this study will be preferentially assigned to Cohort 1. After enrollment into Cohort 2 has been initiated, participants will be assigned to receive treatment of the Cohort 2.
- Conditions
- Hypertension
- Being tested
- GW906
- Keywords
- Hypertension, siRNA, GW906, SAL0132
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GW906Drug
Subcutaneous injection. Expected to be up to 2 years
| Study group | Role | What they receive |
|---|---|---|
| GW906 | Experimental | Subcutaneous injection. Expected to be up to 2 years Receives: Drug: GW906 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to treatment discontinuation
An adverse event (AE) is any untoward medical occurrence in a participant administered with investigational medicinal product, which may manifest as signs, symptoms, disease, or abnormal laboratory findings
Measured: every 3 month, up to 3 years
Secondary outcomes (1)
Change from baseline in mean sitting office systolic blood pressure (msSBP) at the end of Weeks 4, 12, 24, and at each subsequent visit
Change from baseline in mean sitting office systolic blood pressure (msSBP) at the end of Weeks 4, 12, 24, and at each subsequent visit
Measured: Baseline, Weeks 4, 12, 24, up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study start12 Jun 2026
- Primary completion30 Jan 2029 (estimated)
- Study completion30 Jan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Shenzhen Salubris Pharmaceuticals Co., Ltd.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07879755
- Sponsor's protocol ID
- SAL0132A203
- Status last verified
- Sep 2026
- First submitted
- 18 Sep 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of GW906 (SAL0132) Injection in Patients With Essential Hypertension
- ClinicalTrials.gov ID
- NCT07879755
- Acronym / sponsor ID
- SAL0132A203
- Conditions
- Hypertension
- Keywords
- Hypertension, siRNA, GW906, SAL0132
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- 12 Jun 2026 (actual)
- Primary completion
- 30 Jan 2029 (estimated)
- Study completion
- 30 Jan 2029 (estimated)
- First posted
- 19 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical study was designed to assess the safety and efficacy of long-term dosing of GW906
Detailed description
This is an open-label, multicenter, non-randomized, long term extension study. Total study duration is expected to be up to 2 years, with a maximum of 3 years. Participants who have completed the previous GW906 Injection study will be assessed for eligibility at the screening visit of this study. Those who meet the eligibility criteria will receive the first dose of the extension treatment. Participants enrolled in this study will be preferentially assigned to Cohort 1. After enrollment into Cohort 2 has been initiated, participants will be assigned to receive treatment of the Cohort 2.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| GW906 | Experimental | Drug: GW906Subcutaneous injection. Expected to be up to 2 years |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Completed study treatment and the study in accordance with the protocol for GW906 injection.
- Willing to participate in the study and provide written informed consent.
Key exclusion criteria (5 listed)
- Secondary hypertension.
- Orthostatic hypotension accompanied by hypotension-related symptoms was observed in a prior study of GW906 injection.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5× upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; International normalized ratio (INR) > 2.0; Serum potassium > 5.0 mmol/L or < 3.5 mmol/L; eGFR≤30 mL/min/1.73m^2.
- History of any cardiovascular event within 6 months.
- Patients with active malignancy or a history of malignancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GW906Subcutaneous injection. Expected to be up to 2 years | Drug | GW906 |
Primary outcome
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to treatment discontinuation
Time frame: every 3 month, up to 3 years
An adverse event (AE) is any untoward medical occurrence in a participant administered with investigational medicinal product, which may manifest as signs, symptoms, disease, or abnormal laboratory findings
1 secondary outcome
Change from baseline in mean sitting office systolic blood pressure (msSBP) at the end of Weeks 4, 12, 24, and at each subsequent visit
Time frame: Baseline, Weeks 4, 12, 24, up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing GW906 in people with Hypertension, run by Shenzhen Salubris Pharmaceuticals Co., Ltd. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jiguang Wang, Professor (+86-13764189476, jiguangwang@rjh.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and TEAEs leading to treatment discontinuation (time frame: every 3 month, up to 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.